Fidia S.p.A. (BIT:FDA)
0.0040
0.00 (0.00%)
Apr 1, 2025, 3:24 PM CET
Fidia Revenue
Fidia had revenue of 9.42M EUR in the half year ending June 30, 2024, a decrease of -0.16%. This brings the company's revenue in the last twelve months to 29.17M, up 20.45% year-over-year. In the year 2023, Fidia had annual revenue of 28.74M with 16.52% growth.
Revenue (ttm)
29.17M
Revenue Growth
+20.45%
P/S Ratio
0.00
Revenue / Employee
170.57K
Employees
193
Market Cap
124.37K
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 28.74M | 4.07M | 16.52% |
Dec 31, 2022 | 24.66M | 485.00K | 2.01% |
Dec 31, 2021 | 24.18M | 2.52M | 11.65% |
Dec 31, 2020 | 21.65M | -24.55M | -53.13% |
Dec 31, 2019 | 46.20M | -12.65M | -21.50% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Leonardo S.p.a. | 17.76B |
Poste Italiane | 13.48B |
Prysmian | 17.10B |
Iveco Group | 15.29B |
Interpump Group | 2.08B |
Webuild | 11.79B |
Fincantieri | 7.95B |
Maire | 5.86B |
Fidia News
- 4 days ago - FDA OKs Novartis Prostate Cancer Treatment, Triples Eligible Patient Pool - Benzinga
- 4 days ago - Sanofi gets FDA nod for its hemophilia treatment - Seeking Alpha
- 4 days ago - Dabur can sell its toothpaste stock with false labels till May 31: HC - The Times of India
- 4 days ago - Mass layoffs expected to begin at health agencies - NBC News
- 4 days ago - Liquidia says its request for Yutrepia final approval undergoes FDA review - Seeking Alpha
- 4 days ago - Why Is Milestone Pharmaceuticals Stock Plunging Today? - Benzinga
- 4 days ago - Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications - Benzinga
- 4 days ago - Milestone Pharma says FDA declined to approve heart disorder therapy - Seeking Alpha